BIPHETAMINE 20 Drug Patent Profile
✉ Email this page to a colleague
When do Biphetamine 20 patents expire, and when can generic versions of Biphetamine 20 launch?
Biphetamine 20 is a drug marketed by Ucb Inc and is included in one NDA.
The generic ingredient in BIPHETAMINE 20 is amphetamine resin complex; dextroamphetamine resin complex. There are fifty-five drug master file entries for this compound. Additional details are available on the amphetamine resin complex; dextroamphetamine resin complex profile page.
Summary for BIPHETAMINE 20
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | BIPHETAMINE 20 at DailyMed |
US Patents and Regulatory Information for BIPHETAMINE 20
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ucb Inc | BIPHETAMINE 20 | amphetamine resin complex; dextroamphetamine resin complex | CAPSULE, EXTENDED RELEASE;ORAL | 010093-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
